CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer
CareDx (Nasdaq: CDNA) has announced key executive appointments to drive its strategic growth initiatives. Keith Kennedy joins as Chief Operating Officer, bringing over 20 years of healthcare leadership experience. He will lead the company's operational excellence transformation. Jessica Meng becomes Chief Commercial Officer, tasked with driving global commercial growth across CareDx's portfolio. She brings expertise in commercial strategies for pharmaceutical and molecular diagnostics industries.
Additionally, Marica Grskovic, Ph.D., has been appointed Chief Strategy Officer to lead strategic planning and corporate development. These appointments come as CareDx prepares to share its long-term growth strategy during an Investor Day in October 2024. The company focuses on developing healthcare solutions for transplant patients and caregivers.
CareDx (Nasdaq: CDNA) ha annunciato importanti nomine esecutive per guidare le sue iniziative di crescita strategica. Keith Kennedy entra come Chief Operating Officer, portando con sé oltre 20 anni di esperienza nella leadership nel settore sanitario. Guidarà la trasformazione verso l'eccellenza operativa dell'azienda. Jessica Meng diventa Chief Commercial Officer, con il compito di guidare la crescita commerciale globale del portafoglio di CareDx. Porta con sé competenze nelle strategie commerciali per le industrie farmaceutiche e della diagnostica molecolare.
Inoltre, Marica Grskovic, Ph.D., è stata nominata Chief Strategy Officer per guidare la pianificazione strategica e lo sviluppo aziendale. Queste nomine arrivano mentre CareDx si prepara a condividere la sua strategia di crescita a lungo termine durante un Investor Day nell'ottobre 2024. L'azienda si concentra sullo sviluppo di soluzioni sanitarie per pazienti trapiantati e per i loro caregiver.
CareDx (Nasdaq: CDNA) ha anunciado nombramientos ejecutivos clave para impulsar sus iniciativas de crecimiento estratégico. Keith Kennedy se une como Director de Operaciones, aportando más de 20 años de experiencia en liderazgo en el sector salud. Liderará la transformación hacia la excelencia operativa de la empresa. Jessica Meng se convierte en Directora Comercial, encargada de impulsar el crecimiento comercial global del portafolio de CareDx. Aporta experiencia en estrategias comerciales para las industrias farmacéuticas y de diagnósticos moleculares.
Además, Marica Grskovic, Ph.D., ha sido nombrada Directora de Estrategia para liderar la planificación estratégica y el desarrollo corporativo. Estos nombramientos se producen mientras CareDx se prepara para compartir su estrategia de crecimiento a largo plazo durante un Día del Inversor en octubre de 2024. La empresa se centra en desarrollar soluciones de salud para pacientes trasplantados y sus cuidadores.
CareDx (Nasdaq: CDNA)는 전략적 성장 계획을 추진하기 위해 주요 임원 임명을 발표했습니다. Keith Kennedy가 최고 운영 책임자로 합류하며, 20년 이상의 의료 리더십 경험을 가지고 있습니다. 그는 회사의 운영 우수성 변화를 이끌 것입니다. Jessica Meng은 최고 상업 책임자로 임명되어 CareDx의 포트폴리오 전반에 걸쳐 글로벌 상업 성장 추진 임무를 맡게 됩니다. 그녀는 제약 및 분자 진단 산업을 위한 상업 전략에 대한 전문성을 제공합니다.
또한, Marica Grskovic, Ph.D.,가 최고 전략 책임자로 임명되어 전략적 계획 및 기업 개발을 이끌게 됩니다. 이러한 임명은 CareDx가 2024년 10월에 있을 투자자 설명회에서 장기 성장 전략을 공유할 준비를 하는 가운데 이루어졌습니다. 이 회사는 이식 환자 및 보호자를 위한 의료 솔루션 개발에 집중하고 있습니다.
CareDx (Nasdaq: CDNA) a annoncé des nominations exécutives clés pour accompagner ses initiatives de croissance stratégique. Keith Kennedy rejoint en tant que directeur des opérations, apportant plus de 20 ans d'expérience en leadership dans le secteur de la santé. Il dirigera la transformation vers l'excellence opérationnelle de l'entreprise. Jessica Meng devient directrice commerciale, chargée de stimuler la croissance commerciale mondiale du portefeuille de CareDx. Elle apporte son expertise en stratégies commerciales pour les secteurs pharmaceutiques et des diagnostics moléculaires.
De plus, Marica Grskovic, Ph.D., a été nommée directrice de la stratégie pour diriger la planification stratégique et le développement de l'entreprise. Ces nominations interviennent alors que CareDx se prépare à partager sa stratégie de croissance à long terme lors d'une journée des investisseurs en octobre 2024. L'entreprise se concentre sur le développement de solutions de santé pour les patients transplantés et leurs aidants.
CareDx (Nasdaq: CDNA) hat wichtige Führungspositionen bekannt gegeben, um seine strategischen Wachstumsinitiativen voranzutreiben. Keith Kennedy tritt als Chief Operating Officer ein und bringt über 20 Jahre Erfahrung in der Gesundheitsführung mit. Er wird die Transformation des Unternehmens zur operativen Exzellenz leiten. Jessica Meng wird Chief Commercial Officer und hat die Aufgabe, das globale kommerzielle Wachstum über das Portfolio von CareDx voranzutreiben. Sie bringt Expertise in kommerziellen Strategien für die pharmazeutische und molekulardiagnostische Branche mit.
Zusätzlich wurde Marica Grskovic, Ph.D., zur Chief Strategy Officer ernannt, um die strategische Planung und Unternehmensentwicklung zu leiten. Diese Ernennungen erfolgen, während CareDx sich darauf vorbereitet, seine langfristige Wachstumsstrategie während eines Investorentages im Oktober 2024 vorzustellen. Das Unternehmen konzentriert sich auf die Entwicklung von Gesundheitslösungen für Organtransplantationspatienten und deren Angehörige.
- Appointment of experienced executives to key leadership positions
- Focus on operational excellence transformation
- Planned presentation of long-term growth strategy at Investor Day in October 2024
- Expansion of commercial growth initiatives globally
- None.
CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives
Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development
Keith Kennedy brings more than 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contract development and manufacturing organization (CDMO). “CareDx addresses a large transplant market with the potential to profitably scale,” said Kennedy. “I’m thrilled to be a part of this organization and lead the Company’s transformation towards operational excellence.”
As Chief Operating Officer, Kennedy will spearhead CareDx’s operational excellence transformation and lead its operational functions. Kennedy most recently served as Chief Financial Officer at PharmaLogic Holdings Corp. At Veracyte, Kennedy served as Chief Operations Officer, Chief Financial Officer, and Secretary. Kennedy also held key executive positions at MCG Capital Corporation and GE Capital, as well as an Executive Residence at Arlington Capital Partners. He served as an Officer in the
Jessica Meng brings to CareDx deep expertise in building successful commercial strategies for both established companies and entrepreneurial ventures in the pharmaceutical and molecular diagnostics industries. “CareDx is a critical part of the transplant ecosystem and the care of hundreds of thousands of patients. Transplant centers rely on the Company’s testing services, SaaS software solutions, and laboratory products to improve health outcomes,” said Meng. “I’m excited to be a part of the transplant community and work with its incredible clinician leaders on the next generation of CareDx solutions.”
As Chief Commercial Officer Jessica Meng will be responsible for driving CareDx’s commercial growth globally across its portfolio. Meng previously served as Chief Commercial Officer at DELFI Diagnostics, and General Manager of Women's Health at Myovant Sciences. She previously held sales and marketing leadership roles at Veracyte and Genentech. Meng received a Bachelor of Science in Finance and Bachelor of Arts in International Relations with a minor in Mathematics from the University of
Marica Grskovic, Ph.D., has been with CareDx since 2012 where she led the development of the AlloSure® product. As Chief Strategy Officer, Grskovic will lead strategic planning and corporate development at CareDx. She previously held senior leadership roles across Operations, R&D, and Pharma Partnering. Prior to CareDx, Grskovic held scientific roles at the stem cell-based drug discovery platform technology companies iPierian and True North Therapeutics. Grskovic completed her Doctorate in Molecular Biology and Biochemistry.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912469110/en/
Greg Chodaczek
Gilmartin Group
greg@gilmartinir.com
Source: CareDx, Inc.
FAQ
Who are the new executive appointments at CareDx (CDNA)?
What is Keith Kennedy's role at CareDx (CDNA)?
What is Jessica Meng's responsibility at CareDx (CDNA)?
When will CareDx (CDNA) present its long-term growth strategy?
